第十一批国家组织药品集采中选结果即将正式公布 药品集采，新规则带来新变化（民生一线）

Core Viewpoint - The upcoming results of the 11th batch of national organized drug procurement are set to be announced, with new rules focusing on stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion, which aims to foster a healthy environment for the pharmaceutical industry [1][2]. Group 1: Procurement Results - The results of the procurement are expected to be officially announced soon, with patients anticipated to access a new batch of quality and affordable drugs by February 2026 [1]. - A total of 272 companies have qualified for the procurement, covering 55 varieties and 453 products, increasing the total number of drugs included in national organized procurement to 490 [1][2]. Group 2: New Rules and Adjustments - The new procurement rules allow medical institutions to report quantities based on brand names, with 77% of the 46,000 medical institutions opting for brand-specific reporting, facilitating access to lower-priced drugs without changing brands [2][3]. - The procurement emphasizes quality control, raising the bar for companies by requiring a clean record of compliance with production standards and quality management practices [2][3]. Group 3: Market Dynamics and Competition - The introduction of a "reference price" mechanism aims to prevent extreme low pricing and encourages rational bidding among companies, with all bidders required to justify any prices below the reference price [3][4]. - The competitive landscape has intensified, with some products seeing participation from up to 48 companies, indicating a robust supply capacity within the pharmaceutical industry [6][7]. Group 4: Industry Challenges and Future Directions - The procurement aims to reduce medication costs for insured individuals while promoting a shift in the generic drug industry towards quality and innovation, addressing concerns about low profit margins potentially impacting drug quality [5][7]. - Experts suggest that future procurement rules should continue to evolve, emphasizing the need for companies to engage in scientific project selection to avoid oversaturation in the production of similar drugs [7].